Insights

Biotech Innovations Allogene Therapeutics is pioneering the development of innovative allogeneic CAR T cell products for cancer and autoimmune diseases, presenting opportunities for collaboration with institutions and organizations seeking cutting-edge biotechnology solutions.

Funding Expansion Recent funding rounds, including a $15 million grant from the California Institute for Regenerative Medicine, offer opportunities for investment partnerships or joint ventures to support the development of Allogene's investigational products and expand market reach.

Strategic Partnerships Collaborations with companies like UCIHealth and wealth management firms indicate a willingness to partner with different industries, presenting potential avenues for strategic alliances, cross-promotions, or joint marketing efforts.

Investment Attraction Investments from companies like Wealthminder, Inc. and McGlone Suttner Wealth Management Inc. underscore investor confidence in Allogene's potential, providing an opportunity to attract additional financial backing or partnerships from interested investors.

Community Engagement Initiatives such as the CAR T Together program demonstrate a commitment to improving CAR T therapies, showcasing a strong focus on community engagement. Leveraging such initiatives can boost brand reputation and attract customers looking to support socially responsible companies.

Similar companies to Allogene Therapeutics

Allogene Therapeutics Tech Stack

Allogene Therapeutics uses 8 technology products and services including Databricks, OneTrust, Priority Hints, and more. Explore Allogene Therapeutics's tech stack below.

Databricks
Big Data Processing
OneTrust
Cookie Compliance
Priority Hints
Performance
Hadoop
Programming Languages
C#
Programming Languages
New Relic
Real User Monitoring
Autodesk
Visualisation Software
Nginx
Web Servers

Media & News

Allogene Therapeutics's Email Address Formats

Allogene Therapeutics uses at least 1 format(s):

Allogene Therapeutics Email Formats	Example	Percentage
First.Last@allogene.com	John.Doe@allogene.com	96%
Last@allogene.com	Doe@allogene.com	2%
Fir.Last@allogene.com	Joh.Doe@allogene.com	1%
First@allogene.com	John@allogene.com	1%

Frequently Asked Questions

Where is Allogene Therapeutics's headquarters located?

Allogene Therapeutics's main headquarters is located at 210 E Grand Ave South San Francisco, California 94080 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Allogene Therapeutics's phone number?

You can contact Allogene Therapeutics's main corporate office by phone at

+1-650-457-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Allogene Therapeutics's stock symbol?

Allogene Therapeutics is a publicly traded company; the company's stock symbol is ALLO.

What is Allogene Therapeutics's official website and social media links?

Allogene Therapeutics's official website is allogene.com and has social profiles on LinkedIn.

How much revenue does Allogene Therapeutics generate?

As of September 2024, Allogene Therapeutics's annual revenue reached $75M.

What is Allogene Therapeutics's SIC code NAICS code?

Allogene Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Allogene Therapeutics have currently?

As of September 2024, Allogene Therapeutics has approximately 277 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Technology Officer: T. M.Chief People Officer: S. L.Vice President Clinical Operations: A. K.. Explore Allogene Therapeutics's employee directory with LeadIQ.

What industry does Allogene Therapeutics belong to?

Allogene Therapeutics operates in the Biotechnology Research industry.

What technology does Allogene Therapeutics use?

Allogene Therapeutics's tech stack includes DatabricksOneTrustPriority HintsHadoopC#New RelicAutodeskNginx.

What is Allogene Therapeutics's email format?

Allogene Therapeutics's email format typically follows the pattern of . Find more Allogene Therapeutics email formats with LeadIQ.

How much funding has Allogene Therapeutics raised to date?

As of September 2024, Allogene Therapeutics has raised $110M in funding. The last funding round occurred on May 13, 2024 for $110M.

When was Allogene Therapeutics founded?

Allogene Therapeutics was founded in 2017.

Allogene Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. 

For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines

Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.

Company Overview

Headquarters: 210 E Grand Ave South San Francisco, California 94080 US
Phone number: ✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-650-457-****
Website: allogene.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: ALLO
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2017
Employees: 201-500

Media & News

Funding & Financials

$110M
Allogene Therapeutics has raised a total of $110M of funding over 5 rounds. Their latest funding round was raised on May 13, 2024 in the amount of $110M.
$50M$100M
Allogene Therapeutics's revenue is in the range of $50M$100M

Funding & Financials

$110M
Allogene Therapeutics has raised a total of $110M of funding over 5 rounds. Their latest funding round was raised on May 13, 2024 in the amount of $110M.
$50M$100M
Allogene Therapeutics's revenue is in the range of $50M$100M

Company Leadership

T. M.
Chief Technology Officer
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. L.
Chief People Officer
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. K.
Vice President Clinical Operations
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. A.
Vice President Research& Development
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. L.
Vice President And Head Of Clinical Operations
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

A. B.
Chairman Of The Board
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
R. A.
Executive Vice President, Head Of R&d And Chief Medical Officer
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. F.
Owner
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
B. F.
Head Of Supply Chain
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. C.
Head Of Clinical Supply Chain And Global Transportation
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Allogene Therapeutics and Millions of Other Companies
Sign up for full access to Allogene Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Allogene Therapeutics

Autolus Therapeutics

Magenta Therapeutics

Lyell Immunopharma

Natera

Frequency Therapeutics

Editas Medicine

CRISPR Therapeutics

Beam Therapeutics

Allogene Therapeutics Tech Stack

Media & News

Allogene Therapeutics Inc is developing CAR T therapies for cancer and autoimmune diseases.

Allogene Therapeutics Inc is developing AlloCAR T products.

Allogene Therapeutics Inc receives financing of $15M in grant.

Ucihealth invests into Allogene Therapeutics Inc.

Wealthminder, Inc. invests into Allogene Therapeutics Inc $27K.

Allogene Therapeutics Inc launches CAR T Together initiative, aiming to improve CAR T therapies.

Allogene Therapeutics Inc recognized as Debt & Financing category.

Allogene Therapeutics's Email Address Formats

Frequently Asked Questions

Where is Allogene Therapeutics's headquarters located?

What is Allogene Therapeutics's phone number?

What is Allogene Therapeutics's stock symbol?

What is Allogene Therapeutics's official website and social media links?

How much revenue does Allogene Therapeutics generate?

What is Allogene Therapeutics's SIC code NAICS code?

How many employees does Allogene Therapeutics have currently?

What industry does Allogene Therapeutics belong to?

What technology does Allogene Therapeutics use?

What is Allogene Therapeutics's email format?

How much funding has Allogene Therapeutics raised to date?

When was Allogene Therapeutics founded?

Allogene Therapeutics

Company Overview

Media & News

Allogene Therapeutics Inc is developing CAR T therapies for cancer and autoimmune diseases.

Allogene Therapeutics Inc is developing AlloCAR T products.

Allogene Therapeutics Inc receives financing of $15M in grant.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?